News
Agilent Laboratory Achieves Green Lab Certification
Agilent Technologies Inc. (NYSE: A) today announced that the company’s customer demonstration laboratory in Waldbronn, Germany has received the highest level of Green Lab Certification, the gold
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
DGAP-News: Formycon Reports First Quarter 2022 Financial Results and Announces Development Start of two New Biosimilar Candidates FYB208 and FYB209
Waters and BioInfra Establish the ASEAN Academy for Bioanalysis to Promote Analytical Skills Development
Waters Corporation (NYSE:WAT) announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
DGAP-News: BRAIN Biotech publishes first ESG and Sustainability Report
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: Formycon publishes Update on Development Projects
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Humana Receives J.D. Power Award for Best in Customer Satisfaction with Dental Plans
Leading health and well-being company Humana Inc. announced today that it has received the highest ranking in the J.D. Power 2022 U.S Dental Plan Satisfaction Study. In the study results, Humana
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has published important
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an Innovation Passport for the treatment
Agilent Showcases ‘Consistent, Greener, Smarter’ Approach at Analytica 2022
Agilent Technologies Inc. (NYSE: A) today announced that it will showcase its latest workflows and solutions at Analytica 2022, being held 21 to 24 June 2022 in Munich, Germany.
“We are delighted
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Annual General Shareholders’ Meeting 2022: Sonova shareholders approve all motions of the Board of Directors
Humana Healthy Horizons Commits $4.6 Million to Improve Health of Ohioans
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), announced today that it has invested $4.6 million to support community organizations
AMN Healthcare Services, Inc. Announces $250 Million Share Repurchase Program
The Board of Directors (the “Board”) of AMN Healthcare Services, Inc. (NYSE: AMN, the “Company”) authorized an additional $250 million under the Company’s repurchase program for the company’s
Agilent Wins Multiple 2022 Scientists' Choice Awards at ASMS
Agilent Technologies Inc. (NYSE: A) announced that it has received three 2022 Scientists’ Choice Awards including Best New Spectroscopy Product of 2021. Announced at the 70th ASMS Conference on
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and